FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115806629> ?p ?o ?g. }

• W2115806629 endingPage "e81589" @default.
• W2115806629 startingPage "e81589" @default.
• W2115806629 abstract "Chronic rhinosinusitis engenders enormous morbidity in the general population, and is often refractory to medical intervention. Compounds that augment mucociliary clearance in airway epithelia represent a novel treatment strategy for diseases of mucus stasis. A dominant fluid and electrolyte secretory pathway in the nasal airways is governed by the cystic fibrosis transmembrane conductance regulator (CFTR). The objectives of the present study were to test resveratrol, a strong potentiator of CFTR channel open probability, in preparation for a clinical trial of mucociliary activators in human sinus disease.Primary sinonasal epithelial cells, immortalized bronchoepithelial cells (wild type and F508del CFTR), and HEK293 cells expressing exogenous human CFTR were investigated by Ussing chamber as well as patch clamp technique under non-phosphorylating conditions. Effects on airway surface liquid depth were measured using confocal laser scanning microscopy. Impact on CFTR gene expression was measured by quantitative reverse transcriptase polymerase chain reaction.Resveratrol is a robust CFTR channel potentiator in numerous mammalian species. The compound also activated temperature corrected F508del CFTR and enhanced CFTR-dependent chloride secretion in human sinus epithelium ex vivo to an extent comparable to the recently approved CFTR potentiator, ivacaftor. Using inside out patches from apical membranes of murine cells, resveratrol stimulated an ~8 picosiemens chloride channel consistent with CFTR. This observation was confirmed in HEK293 cells expressing exogenous CFTR. Treatment of sinonasal epithelium resulted in a significant increase in airway surface liquid depth (in µm: 8.08+/-1.68 vs. 6.11+/-0.47,control,p<0.05). There was no increase CFTR mRNA.Resveratrol is a potent chloride secretagogue from the mucosal surface of sinonasal epithelium, and hydrates airway surface liquid by increasing CFTR channel open probability. The foundation for a clinical trial utilizing resveratrol as a therapeutic intervention to increase mucociliary transport and airway surface liquid hydration in sinus disease is strongly supported by these findings." @default.
• W2115806629 created "2016-06-24" @default.
• W2115806629 creator A5006333725 @default.
• W2115806629 creator A5006774565 @default.
• W2115806629 creator A5035736153 @default.
• W2115806629 creator A5050704941 @default.
• W2115806629 creator A5050727273 @default.
• W2115806629 creator A5059159168 @default.
• W2115806629 creator A5061587101 @default.
• W2115806629 creator A5075611551 @default.
• W2115806629 date "2013-11-25" @default.
• W2115806629 modified "2023-10-18" @default.
• W2115806629 title "Resveratrol Enhances Airway Surface Liquid Depth in Sinonasal Epithelium by Increasing Cystic Fibrosis Transmembrane Conductance Regulator Open Probability" @default.
• W2115806629 cites W1818757956 @default.
• W2115806629 cites W1881147845 @default.
• W2115806629 cites W1964050294 @default.
• W2115806629 cites W1985121334 @default.
• W2115806629 cites W1996215008 @default.
• W2115806629 cites W1997415154 @default.
• W2115806629 cites W1998848618 @default.
• W2115806629 cites W2004978232 @default.
• W2115806629 cites W2022824867 @default.
• W2115806629 cites W2035131077 @default.
• W2115806629 cites W2038048838 @default.
• W2115806629 cites W2039056646 @default.
• W2115806629 cites W2040695610 @default.
• W2115806629 cites W2052436780 @default.
• W2115806629 cites W2053346291 @default.
• W2115806629 cites W2064883859 @default.
• W2115806629 cites W2072334346 @default.
• W2115806629 cites W2077732883 @default.
• W2115806629 cites W2080212245 @default.
• W2115806629 cites W2109696371 @default.
• W2115806629 cites W2114700246 @default.
• W2115806629 cites W2117300004 @default.
• W2115806629 cites W2121996960 @default.
• W2115806629 cites W2128377922 @default.
• W2115806629 cites W2131284004 @default.
• W2115806629 cites W2131552211 @default.
• W2115806629 cites W2137075043 @default.
• W2115806629 cites W2148114189 @default.
• W2115806629 cites W2150712887 @default.
• W2115806629 doi "https://doi.org/10.1371/journal.pone.0081589" @default.
• W2115806629 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3888307" @default.
• W2115806629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24282612" @default.
• W2115806629 hasPublicationYear "2013" @default.
• W2115806629 type Work @default.
• W2115806629 sameAs 2115806629 @default.
• W2115806629 citedByCount "39" @default.
• W2115806629 countsByYear W21158066292014 @default.
• W2115806629 countsByYear W21158066292015 @default.
• W2115806629 countsByYear W21158066292016 @default.
• W2115806629 countsByYear W21158066292017 @default.
• W2115806629 countsByYear W21158066292018 @default.
• W2115806629 countsByYear W21158066292019 @default.
• W2115806629 countsByYear W21158066292020 @default.
• W2115806629 countsByYear W21158066292021 @default.
• W2115806629 countsByYear W21158066292023 @default.
• W2115806629 crossrefType "journal-article" @default.
• W2115806629 hasAuthorship W2115806629A5006333725 @default.
• W2115806629 hasAuthorship W2115806629A5006774565 @default.
• W2115806629 hasAuthorship W2115806629A5035736153 @default.
• W2115806629 hasAuthorship W2115806629A5050704941 @default.
• W2115806629 hasAuthorship W2115806629A5050727273 @default.
• W2115806629 hasAuthorship W2115806629A5059159168 @default.
• W2115806629 hasAuthorship W2115806629A5061587101 @default.
• W2115806629 hasAuthorship W2115806629A5075611551 @default.
• W2115806629 hasBestOaLocation W21158066291 @default.
• W2115806629 hasConcept C114682108 @default.
• W2115806629 hasConcept C126322002 @default.
• W2115806629 hasConcept C142724271 @default.
• W2115806629 hasConcept C145822097 @default.
• W2115806629 hasConcept C164718446 @default.
• W2115806629 hasConcept C185592680 @default.
• W2115806629 hasConcept C2776502428 @default.
• W2115806629 hasConcept C2776816829 @default.
• W2115806629 hasConcept C2776938444 @default.
• W2115806629 hasConcept C2777714996 @default.
• W2115806629 hasConcept C2778428886 @default.
• W2115806629 hasConcept C2779932011 @default.
• W2115806629 hasConcept C2908647359 @default.
• W2115806629 hasConcept C3018436504 @default.
• W2115806629 hasConcept C529295009 @default.
• W2115806629 hasConcept C55493867 @default.
• W2115806629 hasConcept C71924100 @default.
• W2115806629 hasConcept C86803240 @default.
• W2115806629 hasConcept C87568996 @default.
• W2115806629 hasConcept C95444343 @default.
• W2115806629 hasConcept C98274493 @default.
• W2115806629 hasConcept C99454951 @default.
• W2115806629 hasConceptScore W2115806629C114682108 @default.
• W2115806629 hasConceptScore W2115806629C126322002 @default.
• W2115806629 hasConceptScore W2115806629C142724271 @default.
• W2115806629 hasConceptScore W2115806629C145822097 @default.
• W2115806629 hasConceptScore W2115806629C164718446 @default.
• W2115806629 hasConceptScore W2115806629C185592680 @default.
• W2115806629 hasConceptScore W2115806629C2776502428 @default.
• W2115806629 hasConceptScore W2115806629C2776816829 @default.

• next